| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5849535 | PHARMACIA | Human growth hormone variants |
Mar, 2017
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6057292 | PHARMACIA | Method for inhibiting growth hormone action |
Sep, 2015
(8 years ago) | |
Somavert is owned by Pharmacia.
Somavert contains Pegvisomant.
Somavert has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Somavert are:
- US6057292
- US5849535
Somavert was authorised for market use on 31 July, 2014.
Somavert is available in injectable;subcutaneous dosage forms.
Somavert can be used as acromegaly in patients w/inadequate response to surgery and/or radiation therapy and/or medical therapies, or for whom these therapies are not appropriate.
The generics of Somavert are possible to be released after 25 March, 2017.
Drugs and Companies using PEGVISOMANT ingredient
Market Authorisation Date: 31 July, 2014
Treatment: Acromegaly in patients w/inadequate response to surgery and/or radiation therapy and/or medical therapies, or for whom these therapies are not appropriate
Dosage: INJECTABLE;SUBCUTANEOUS
SOMAVERT family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6057292 | PHARMACIA AND UPJOHN | Method for inhibiting growth hormone action |
Sep, 2015
(8 years ago) | |
| US5849535 | PHARMACIA AND UPJOHN | Human growth hormone variants |
Mar, 2017
(7 years ago) | |
Somavert is owned by Pharmacia And Upjohn.
Somavert contains Pegvisomant.
Somavert has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Somavert are:
- US6057292
- US5849535
Somavert was authorised for market use on 31 July, 2014.
Somavert is available in injectable;subcutaneous dosage forms.
Somavert can be used as acromegaly in patients w/inadequate response to surgery and/or radiation therapy and/or medical therapies, or for whom these therapies are not appropriate.
The generics of Somavert are possible to be released after 25 March, 2017.
Drugs and Companies using PEGVISOMANT ingredient
Market Authorisation Date: 31 July, 2014
Treatment: Acromegaly in patients w/inadequate response to surgery and/or radiation therapy and/or medical therapies, or for whom these therapies are not appropriate
Dosage: INJECTABLE;SUBCUTANEOUS
SOMAVERT family patents